VCEL Vericel Dashboard

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.

Company profile

Ticker

VCEL

Exchange

NASDAQ

Website

vcel.com

CEO

Dominick Colangelo

Incorporated

Michigan

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Exelixis ...

Former names

AASTROM BIOSCIENCES INC

SEC CIK

0000887359

Corporate docs

Articles of Incorporation & Bylaws

IRS number

943096597

VCEL stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

1 Aug 21

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

58 Biggest Movers From Yesterday

30 Jun 21

Gainers

Why Shares Of MediWound And Vericel Fell On Tuesday

29 Jun 21

Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Biologics License Application.

12 Health Care Stocks Moving In Tuesday's Intraday Session

29 Jun 21

FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop

29 Jun 21

Press releases

Pro users get this 30m faster

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vericel Corporation - VCEL

18 Jul 21

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL). Such investors are advised to

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vericel Corporation - VCEL

5 Jul 21

New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation ("Vericel" or the "Company") (NASDAQ:VCEL). Such investors are advised to

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vericel Corporation - VCEL

29 Jun 21

NEW YORK, June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL). Such investors are advised to

MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application

29 Jun 21

Vericel Provides Regulatory Update for NexoBrid

29 Jun 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

5 May 21

2 Aug 21

31 Dec 21

Financial summary

Financial statements Chart VCEL financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Vericel earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	58.37M	58.37M	58.37M	58.37M	58.37M	58.37M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	1.1M	(positive/no burn)	(positive/no burn)	(positive/no burn)
Cash used (since last report)	n/a	n/a	4.5M	n/a	n/a	n/a
Cash remaining	n/a	n/a	53.86M	n/a	n/a	n/a
Runway (months of cash)	n/a	n/a	48.9	n/a	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

VCEL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Jul 21	Sean C. Flynn	Common Stock	Sell	Dispose S	No	Yes	55.01	2,800	154.03K	2,419
21 Jul 21	Sean C. Flynn	Common Stock	Option exercise	Aquire M	No	No	16.25	2,800	45.5K	5,219
21 Jul 21	Sean C. Flynn	Stock Option Common Stock	Option exercise	Dispose M	No	No	16.25	2,800	45.5K	137,200
15 Jul 21	Sean C. Flynn	Common Stock	Sell	Dispose S	No	Yes	51.1786	10,000	511.79K	2,419
15 Jul 21	Sean C. Flynn	Common Stock	Option exercise	Aquire M	No	No	16.25	10,000	162.5K	12,419
15 Jul 21	Sean C. Flynn	Stock Option Common Stock	Option exercise	Dispose M	No	No	16.25	10,000	162.5K	140,000
12 Jul 21	Halpin Michael	Common Stock	Sell	Dispose S	No	Yes	53.5438	20,000	1.07M	5,623
12 Jul 21	Halpin Michael	Common Stock	Option exercise	Aquire M	No	No	2.65	20,000	53K	25,623
12 Jul 21	Halpin Michael	Stock Option Common Stock	Option exercise	Dispose M	No	No	2.65	20,000	53K	27,063
30 Jun 21	Joseph Anthony Mara Jr	Common Stock	Payment of exercise	Dispose F	No	No	52.5	1,174	61.64K	5,848

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

VCEL institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	201	166	+21.1%
Opened positions	62	43	+44.2%
Closed positions	27	13	+107.7%
Increased positions	57	50	+14.0%
Reduced positions	66	56	+17.9%

13F shares	Current	Prev Q	Change
Total value	5.42B	2.06B	+162.9%
Total shares	49.48M	45.42M	+8.9%
Total puts	64.4K	46.7K	+37.9%
Total calls	113.5K	55.2K	+105.6%
Total put/call ratio	0.6	0.8	-32.9%

Largest owners	Shares	Value	Change
BLK Blackrock	7.26M	$403.34M	+120.5%
Brown Capital Management	4.57M	$253.87M	+13.6%
RTW Investments	4.52M	$250.95M	0.0%
Vanguard	2.94M	$163.36M	+26.0%
Fred Alger Management	2.72M	$151.32M	NEW
WDR Waddell & Reed Financial	2.69M	$149.48M	-2.8%
STT State Street	2.43M	$134.99M	+11.1%
FHI Federated Hermes	1.54M	$85.42M	+12.0%
WFC Wells Fargo & Co.	1.04M	$57.52M	-14.5%
Next Century Growth Investors	1.01M	$55.89M	-26.6%

Largest transactions	Shares	Bought/sold	Change
BLK Blackrock	7.26M	+3.97M	+120.5%
Fred Alger Management	2.72M	+2.72M	NEW
UBS UBS Group AG - Registered Shares	10.01K	-908.2K	-98.9%
Great Point Partners	0	-900K	EXIT
Granahan Investment Management	376.23K	-715.61K	-65.5%
Vanguard	2.94M	+607.67K	+26.0%
Kopp Family Office	574.08K	-576.66K	-50.1%
Brown Capital Management	4.57M	+547.28K	+13.6%
BNP Paribas Asset Management Holding	452.37K	-544.17K	-54.6%
Artisan Partners Limited Partnership	958.45K	+443.8K	+86.2%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

ThermoGenesis • BioCardia • Athersys • Ocugen • Cellular Biomedicine • Regenicin • MyoKardia • Biostage • AVITA Medical

Management Discussion

Our net loss for the three months ended March 31, 2021 and 2020 totaled $3.3 million and $4.7 million, respectively.
Net revenue increased for the three months ended March 31, 2021 compared to the same period in 2020, driven by strong volume growth for both MACI and Epicel. Additionally, during the three months ended March 31, 2021, we recorded $0.9 million of revenue associated with delivery of NexoBrid to BARDA for emergency response preparedness.
Net revenue for the three months ended March 31, 2021 and 2020 are shown below.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: assure, autumn, bromelain, Canada, cessation, cGMP, Chemistry, CMC, competitive, compliance, cycle, damage, degree, dissipated, diversion, enriched, fallen, fell, fringe, guide, human, implied, ineffective, infection, inoculate, Israel, Litigation, lockdown, mentioned, Mexico, month, NaN, outcome, outset, overseen, pathway, payable, pivotal, Practice, prevent, professional, pronounced, proteolytic, quality, Reform, render, rent, resuming, risen, rose, senior, sought, speak, spring, strong, summer, Taiwan, transmission, turn, unrecognized, urging, usage, vaccine, wave, widely, worsening, wrong

Removed: anonyme, apply, assessed, assumption, automated, banning, base, beginning, book, calling, candidate, cardiomyopathy, China, clarity, close, consistent, construction, DCM, declared, developed, dilated, discretionary, downturn, exempt, expanded, factor, framework, French, fund, heart, implemented, improve, incorporate, incurred, infrastructure, initiate, instituting, instruction, instrument, interim, involve, liquidity, location, lost, lower, lowering, macroeconomic, marrow, measure, measuring, minimize, modify, multicellular, occurring, organization, originated, paragraph, preapproval, President, proprietary, purpose, Quarterly, rapidly, recent, recognize, recommended, reducing, representing, Sanofi, scalable, shelter, spending, stage, statement, supportable, suspending, system, temporarily, Topic, unanticipated, undue, unique, workforce, Wuhan

From filing 10-Q 2021 Q1